Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

493
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
493
T Cell Types and Functions01:24

T Cell Types and Functions

756
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
756
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

203
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
203
Autoimmune Disorders01:29

Autoimmune Disorders

374
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
374
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

314
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
314

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Predictors of relapse, early escalation and 1-Year use of glucocorticoids in new-onset polymyalgia rheumatica: A prospective cohort study.

Seminars in arthritis and rheumatism·2026
Same journal

Postoperative complications and outcomes after surgical treatment for tophaceous gout: A systematic review and meta-analysis.

Seminars in arthritis and rheumatism·2026
Same journal

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same journal

Effectiveness and safety of primary thromboprophylaxis in antiphospholipid antibody carriers by serological 2023 ACR/EULAR domains.

Seminars in arthritis and rheumatism·2026
Same journal

Clustering-based stratification of fibromyalgia subtypes: A comparative analysis of medicated and non-medicated cohorts from two academic centers.

Seminars in arthritis and rheumatism·2026
Same journal

Imaging techniques for assessing the hand in systemic sclerosis: a systematic review.

Seminars in arthritis and rheumatism·2026
See all related articles

Related Experiment Video

Updated: May 23, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.7K

Pathogenesis and targets in uveitis.

Professor Athimalaipet V Ramanan1

  • 1Department of Paediatric Rheumatology, Bristol Royal Hospital for Children, UK.

Seminars in Arthritis and Rheumatism
|March 7, 2025
PubMed
Summary
This summary is machine-generated.

Uveitis, an eye condition common in rheumatic diseases like rheumatoid arthritis, poses a sight threat. Current treatments for rheumatic diseases lack robust evidence for managing associated uveitis effectively.

Keywords:
Ankylosing spondylitisBiologicsJuvenile idiopathic arthritisPsoriatic arthritisRheumatoid arthritisVeitis

More Related Videos

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.6K
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.2K

Related Experiment Videos

Last Updated: May 23, 2025

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
07:40

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model

Published on: January 12, 2022

4.7K
Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis
10:33

Primed Mycobacterial Uveitis PMU as a Model for Post-Infectious Uveitis

Published on: December 17, 2021

2.6K
Induction of Ocular Surface Inflammation and Collection of Involved Tissues
06:38

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

2.2K

Area of Science:

  • Ophthalmology and Rheumatology
  • Systemic Rheumatic Diseases and Ocular Complications

Background:

  • Uveitis is a frequent ocular manifestation in patients with systemic rheumatic diseases.
  • It can be an independent condition or associated with systemic autoimmune disorders.
  • Rheumatic diseases like rheumatoid arthritis (RA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and psoriatic arthritis (PsA) are frequently linked to uveitis.

Purpose of the Study:

  • To highlight the prevalence of uveitis in systemic rheumatic diseases.
  • To underscore the limited evidence base for managing ocular complications, specifically uveitis, despite advances in systemic therapies for rheumatic conditions.

Main Methods:

  • Review of current literature on uveitis in the context of systemic rheumatic diseases.
  • Analysis of the evidence supporting management strategies for ocular complications in RA, AS, JIA, and PsA.

Main Results:

  • Significant therapeutic advancements exist for systemic rheumatic diseases (RA, AS, JIA, PsA).
  • However, the evidence for managing the specific ocular complication, uveitis, remains limited.
  • Uveitis represents a potentially sight-threatening condition requiring dedicated management strategies.

Conclusions:

  • There is a critical need for more research into the effective management of uveitis associated with systemic rheumatic diseases.
  • Bridging the gap between systemic treatment advances and ocular complication management is essential for preserving vision in affected patients.